PortalPublikationenTen-year data on 138 patients with endometrial carcinoma and...

Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients

Standard

Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. / Röper, B; Astner, S T; Heydemann-Obradovic, A; Thamm, R; Jacob, V; Hölzel, D; Schmalfeldt, B; Kiechle-Bahat, M; Höss, C; Molls, M.

in: GYNECOL ONCOL, Jahrgang 107, Nr. 3, 12.2007, S. 541-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Röper, B, Astner, ST, Heydemann-Obradovic, A, Thamm, R, Jacob, V, Hölzel, D, Schmalfeldt, B, Kiechle-Bahat, M, Höss, C & Molls, M 2007, 'Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients', GYNECOL ONCOL, Jg. 107, Nr. 3, S. 541-8. https://doi.org/10.1016/j.ygyno.2007.08.055

APA

Röper, B., Astner, S. T., Heydemann-Obradovic, A., Thamm, R., Jacob, V., Hölzel, D., Schmalfeldt, B., Kiechle-Bahat, M., Höss, C., & Molls, M. (2007). Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. GYNECOL ONCOL, 107(3), 541-8. https://doi.org/10.1016/j.ygyno.2007.08.055

Vancouver

Röper B, Astner ST, Heydemann-Obradovic A, Thamm R, Jacob V, Hölzel D et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. GYNECOL ONCOL. 2007 Dez;107(3):541-8. https://doi.org/10.1016/j.ygyno.2007.08.055

Bibtex

@article{acd203feda6d46c29c70cc0e2f118875,
title = "Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients",
abstract = "OBJECTIVE: To evaluate long-term outcome, risk factors, and causes of death in stage I-IIIA endometrial carcinoma (EC) patients treated only with adjuvant vaginal brachytherapy (VB) and to clarify for which subgroups of patients it is safe to omit external-beam radiotherapy (EBRT).METHODS: Out of 224 EC patients receiving postoperative radiotherapy between 1990 and 2002, 138 had VB alone in curative intent (FIGO [2002]: 85%I, 12%II, 3%IIIA; 18 low risk [IA G1-2, IB G1], 103 intermediate risk [IB G2-3, IC G1-2, IIA-B G1-2], 17 high risk [IC G3, IIIA]). After surgery+/-lymphadenectomy, HDR-brachytherapy prescription (in 95.7% of patients) was 3x10 Gy to the surface or 3x5 Gy at 5 mm tissue depths.RESULTS: Median follow-up was 107 months (range 3-185). Three intermediate and 7 high risk-patients relapsed. The 10-year vaginal control was 99.2%, locoregional control was 95.2% (low/intermediate/high risk: 100%/98.9%/68.8%), and disease-free survival (DFS) was 91.7% (100%/96.8%/55.2%). Risk factors for poor DFS were lymphovascular space invasion, > or = 50% myometrial invasion (univariate, p<0.05), pathological FIGO-stage, and grade 3 (uni-/multivariate, p<0.05). Leading causes of deaths (n=41) were cardiovascular disease (29%) and other malignancies (24%) ahead of EC (19.5%). The 10-year overall survival was 68.5% and the disease-specific survival was 92.4%. Thirty-five secondary tumors in 31 patients led to a higher actuarial death rate (10-year 9.9%, 15-year 17.7%) than EC (7.6%).CONCLUSIONS: Restricting adjuvant therapy to VB alone seems to be safe in low and intermediate risk EC and can be recommended. As death rarely relates to early-stage EC, value of adjuvant therapy is probably better reflected by DFS rather than by overall survival.",
keywords = "Adult, Aged, Aged, 80 and over, Brachytherapy, Disease-Free Survival, Endometrial Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Risk Factors, Survival Rate, Vagina",
author = "B R{\"o}per and Astner, {S T} and A Heydemann-Obradovic and R Thamm and V Jacob and D H{\"o}lzel and B Schmalfeldt and M Kiechle-Bahat and C H{\"o}ss and M Molls",
year = "2007",
month = dec,
doi = "10.1016/j.ygyno.2007.08.055",
language = "English",
volume = "107",
pages = "541--8",
journal = "GYNECOL ONCOL",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients

AU - Röper, B

AU - Astner, S T

AU - Heydemann-Obradovic, A

AU - Thamm, R

AU - Jacob, V

AU - Hölzel, D

AU - Schmalfeldt, B

AU - Kiechle-Bahat, M

AU - Höss, C

AU - Molls, M

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVE: To evaluate long-term outcome, risk factors, and causes of death in stage I-IIIA endometrial carcinoma (EC) patients treated only with adjuvant vaginal brachytherapy (VB) and to clarify for which subgroups of patients it is safe to omit external-beam radiotherapy (EBRT).METHODS: Out of 224 EC patients receiving postoperative radiotherapy between 1990 and 2002, 138 had VB alone in curative intent (FIGO [2002]: 85%I, 12%II, 3%IIIA; 18 low risk [IA G1-2, IB G1], 103 intermediate risk [IB G2-3, IC G1-2, IIA-B G1-2], 17 high risk [IC G3, IIIA]). After surgery+/-lymphadenectomy, HDR-brachytherapy prescription (in 95.7% of patients) was 3x10 Gy to the surface or 3x5 Gy at 5 mm tissue depths.RESULTS: Median follow-up was 107 months (range 3-185). Three intermediate and 7 high risk-patients relapsed. The 10-year vaginal control was 99.2%, locoregional control was 95.2% (low/intermediate/high risk: 100%/98.9%/68.8%), and disease-free survival (DFS) was 91.7% (100%/96.8%/55.2%). Risk factors for poor DFS were lymphovascular space invasion, > or = 50% myometrial invasion (univariate, p<0.05), pathological FIGO-stage, and grade 3 (uni-/multivariate, p<0.05). Leading causes of deaths (n=41) were cardiovascular disease (29%) and other malignancies (24%) ahead of EC (19.5%). The 10-year overall survival was 68.5% and the disease-specific survival was 92.4%. Thirty-five secondary tumors in 31 patients led to a higher actuarial death rate (10-year 9.9%, 15-year 17.7%) than EC (7.6%).CONCLUSIONS: Restricting adjuvant therapy to VB alone seems to be safe in low and intermediate risk EC and can be recommended. As death rarely relates to early-stage EC, value of adjuvant therapy is probably better reflected by DFS rather than by overall survival.

AB - OBJECTIVE: To evaluate long-term outcome, risk factors, and causes of death in stage I-IIIA endometrial carcinoma (EC) patients treated only with adjuvant vaginal brachytherapy (VB) and to clarify for which subgroups of patients it is safe to omit external-beam radiotherapy (EBRT).METHODS: Out of 224 EC patients receiving postoperative radiotherapy between 1990 and 2002, 138 had VB alone in curative intent (FIGO [2002]: 85%I, 12%II, 3%IIIA; 18 low risk [IA G1-2, IB G1], 103 intermediate risk [IB G2-3, IC G1-2, IIA-B G1-2], 17 high risk [IC G3, IIIA]). After surgery+/-lymphadenectomy, HDR-brachytherapy prescription (in 95.7% of patients) was 3x10 Gy to the surface or 3x5 Gy at 5 mm tissue depths.RESULTS: Median follow-up was 107 months (range 3-185). Three intermediate and 7 high risk-patients relapsed. The 10-year vaginal control was 99.2%, locoregional control was 95.2% (low/intermediate/high risk: 100%/98.9%/68.8%), and disease-free survival (DFS) was 91.7% (100%/96.8%/55.2%). Risk factors for poor DFS were lymphovascular space invasion, > or = 50% myometrial invasion (univariate, p<0.05), pathological FIGO-stage, and grade 3 (uni-/multivariate, p<0.05). Leading causes of deaths (n=41) were cardiovascular disease (29%) and other malignancies (24%) ahead of EC (19.5%). The 10-year overall survival was 68.5% and the disease-specific survival was 92.4%. Thirty-five secondary tumors in 31 patients led to a higher actuarial death rate (10-year 9.9%, 15-year 17.7%) than EC (7.6%).CONCLUSIONS: Restricting adjuvant therapy to VB alone seems to be safe in low and intermediate risk EC and can be recommended. As death rarely relates to early-stage EC, value of adjuvant therapy is probably better reflected by DFS rather than by overall survival.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Brachytherapy

KW - Disease-Free Survival

KW - Endometrial Neoplasms

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Retrospective Studies

KW - Risk Factors

KW - Survival Rate

KW - Vagina

U2 - 10.1016/j.ygyno.2007.08.055

DO - 10.1016/j.ygyno.2007.08.055

M3 - SCORING: Journal article

C2 - 17884152

VL - 107

SP - 541

EP - 548

JO - GYNECOL ONCOL

JF - GYNECOL ONCOL

SN - 0090-8258

IS - 3

ER -